A5060722923- Lung Cancer Treatments and Mutations
- Organ Transplantation Techniques and Outcomes
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Organ Donation and Transplantation
- Lung Cancer Research Studies
- Prostate Cancer Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Lung Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Liver Disease Diagnosis and Treatment
- Renal and related cancers
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Head and Neck Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Urinary and Genital Oncology Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Lipids, and Metabolism
- Cancer-related molecular mechanisms research
- Renal cell carcinoma treatment
Vedanta Resources (India)
2025
Bhaktivedanta Hospital & Research Institute
2014-2024
Care Institute of Medical Sciences
2009-2023
Institute of Medical Sciences
2008-2021
Birmingham City Hospital
2021
Heartlands Hospital
2021
Sandwell General Hospital
2021
Apollo Hospitals
2020
Axis Multispecialty Hospital
2017
Eastern Cooperative Oncology Group
2014
Background Worldwide, lung cancer stands as a leading cause of mortality, with EGFR-mutated metastatic non-small cell (NSCLC) accounting for large percentage cases in the Indian population. Different generations EGFR-tyrosine kinase inhibitors (TKIs) are available to treat NSCLC. The purpose our research was evaluate and compare superiority osimertinib over gefitinib/erlotinib terms clinical effectiveness safety. Methods A retrospective observational cohort study conducted at Clinical...
Abstract Lorlatinib is approved in India for patients with previously treated anaplastic lymphoma kinase (ALK)–positive advanced or recurrent non-small-cell lung cancer (NSCLC). Owing to the limited number of Indian phase I/II and III studies, a postapproval study was conducted report safety efficacy lorlatinib this patient population. In IV study, unresectable and/or ALK-positive NSCLC resistant intolerant ≥1 prior ALK inhibitor were lorlatinib. The primary endpoint investigator-assessed...
Purpose Cancer treatments can impact various aspects of quality life patients. This study aims to determine number women who report changes in appearance due cancer treatment and if they related it their confidence on sexual relationships with partners. Design/methodology/approach For current study, responses from cancer, inquiring about experiences pertaining appearance, intimacy partner context diagnosis treatment, were recorded statistically analysed. It was compared same for patients...
Background: The organ supply shortage continues to be a public health care crisis, with nearly 20 people dying each day awaiting transplantation. Inability obtain consent remains one of the major obstacles converting potential donors into donors. We hypothesize that presence in-house coordinators (IHCs) from procurement organizations (OPOs) will improve donor conversion rates. Methods: This retrospective review analyzed effect an IHC program on donation outcome. Referrals for possible three...
Paclitaxel is widely used in the treatment of patients with metastatic breast cancer (MBC). Formulations paclitaxel contain surfactants and solvents or albumin derived from human blood. The use co-solvents such as polyoxyethylated castor oil thought to contribute toxicity profile hypersensitivity reactions well leaching plasticizers polyvinyl chloride bags infusion sets. Currently, nab-paclitaxel, an albumin-bound nanometer range continues be preferred taxane formulation clinic. This study...
Background: A persistent shortage of organs and inexhaustible waiting lists continue to result in many people dying while awaiting transplantation. On July 1, 2006, the California Department Motor Vehicles joined forces with California's Online Organ Tissue Registry launched a campaign increase donation rates. This included intense public media education. The efficacy such on donor demographics has not been studied. Methods: Retrospective analysis was conducted organ referrals donations from...
The phase 3 JAVELIN Bladder 100 trial showed significantly prolonged overall survival (OS) with avelumab first-line maintenance + best supportive care (BSC) vs. BSC alone in patients advanced urothelial carcinoma (UC) that had not progressed platinum-containing chemotherapy. Here, efficacy and safety were assessed from the initial analysis of (data cutoff October 21, 2019) enrolled Asian countries.Patients locally or metastatic UC 4 to 6 cycles chemotherapy (gemcitabine cisplatin...
E X C U T I V S M A R Y The document is based on consensus among the experts and best available evidence pertaining to Indian population meant for practice in India. Early diagnosis imperative improving outcomes preserving quality of life. High index suspicion be maintained leukoplakia (high risk site). Evaluation a patient with newly diagnosed tongue cancer should include essential tests: Magnetic resonance imaging (MRI) investigative modality choice when indicated. Computed tomography (CT)...
The management of hormone receptor-positive Her2-negative breast cancer patients with advanced or metastatic disease is a common problem in India and other countries this region. This expert group used data from published literature, practical experience, opinion large academic oncologists, to arrive at consensus recommendations for use by the community oncologists.
Abstract Breast cancer is a public health challenge globally as well in India. Improving outcome and cure requires appropriate biomarker testing to assign risk plan treatment. Because it documented that significant ethnic geographical variations biological genetic features exist worldwide, such biomarkers need be validated approved by authorities the region where these are intended used. The use of western guidelines, for Caucasian population, can lead inappropriate overtreatment or...
We conducted a survey of 111 medical oncologists across India to understand the current pattern epidermal growth factor receptor (EGFR) mutation testing at their respective centers.Medical from institutes were interviewed face using structured questionnaire. They divided into two groups - Group 1 with in-house EGFR and 2 who send samples central/commercial laboratories outside institutions. Answers analyzed see prevailing patterns differences between if any.Ninety-five percent (105/111)...
Introduction Squamous cell carcinoma of the head and neck region (HNSCC) remains an important problem for majority countries developing world. Most patients present with advanced disease. Hence, it is a challenge to improve cure rates as well provide meaningful survival advantage others. In India alone, estimated that more than 2.5 lakh new are diagnosed every year, whom about three-fourths in stage. The population-based cancer registry Indian Cancer Society shows number HNSCC increasing...
1069 Background: PICN is a novel, solvent- and protein-free, 100-110 nm particle formulation of paclitaxel stabilized with polymer lipids using Nanotecton Technology. We compared the safety efficacy at two different doses versus albumin-stabilized nanoparticle in 3-weekly schedule subjects MBC. Methods: In this randomized, controlled non-inferiority trial,180 aged18-65 years, MBC, ECOG performance status ≤ 2, estimated survival ≥ 12 weeks adequate organ function, were enrolled randomly...
e13111 Background: Lung cancer diagnosis now involves routine use of biomarker testing to identify the driver mutations. We conducted a survey 111 medical oncologists across India understand current pattern EGFR mutation at their respective centres. Methods: Medical from institutes were interviewed face using structured questionnaire. They divided into two groups - Group 1 with in-house and 2 who send samples central/commercial labs. Answers analysed see prevailing patterns differences...
Abstract Introduction: Efatutazone is a potent, highly selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist active in preclinical cancer models, including NSCLC. In phase 1 studies, efatutazone showed anticancer activity and manageable safety profile. An vitro study combining PPARγ an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), similar to erlotinib, increase the antiproliferative effects of EGFR-TKI NSCLC cells (Lee et al. Lung Cancer. 2006). This...